You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
陈肇始:豁免科兴医学期刊数据绝非降低标准
阿思达克 02-08 09:21
食物及卫生局局长陈肇始表示,科兴已向政府提交部分曾交国家药监局审批的第三期临床试验数据,争取在农历新年前交由疫苗顾问专家委员会审议,并尽快批核作紧急使用,强调政府豁免科兴在医学期刊刊登研究数据绝非降低标准,指出顾问专家委员会将小心审视每只疫苗的所有数据,希望公众对专家小组予以信心。

陈肇始在电台节目中表示,正与复星医药(02196.HK)及德国药厂BioNTech紧密联系,希望疫苗能在本月底送货,争取在农历新年过後安排市民接种。

她又提到,18区疫苗接种中心的筹备工作如火如荼,创科局将推出预约接种疫苗的网上平台,让市民预约及提醒他们接种第二剂疫苗,并会邀请私家医生参与疫苗接种计划,并安排使用不需冷藏在摄氏负70度的科兴疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account